No Data
Hot Stocks Digest (Morning Session): Mitsubishi Paper, Honda, Axel M, ETC.
Significant drop. The third quarter financial results were announced the previous day, with an operating profit of 5.58 billion yen, a 13.4% increase from the same period last year, and for the period from September to November, it was 0.82 billion yen, an increase of 16.5%.
The Tokyo Stock Exchange Growth Index continued to decline, widening the drop towards the end.
Tokyo Stock Exchange Growth Market Index 802.31 -7.72 / Volume 0.2 billion 51.13 million shares / Trading value 130.9 billion yen Tokyo Stock Exchange Growth Market 250 Index 624.89 -5.96 / Volume 0.1 billion 38.5 million shares / Trading value 94.7 billion yen. Today's Growth Market saw both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index continue to decline, with the number of advancing stocks at 202, declining stocks at 364, and unchanged at 37. The Growth Market experienced a soft development today. The previous day, on the 19th, in the USA.
Chiome Bioscience Unveils Promising Cancer Therapy Data
Hot Stocks Digest (Morning Session): Fujita Corporation, Toho Lead, AndDo, ETC.
Fujita Corporation <3370>: 294 yen (+74 yen) briefly reached the daily limit up. A new shareholder benefit program has been announced. For shareholders holding more than 100 shares as of the end of March, a 1000 yen web coupon will be presented. The purpose of the new benefit is to deepen understanding of the business by experiencing the company's products and services, increase the appeal of investing in Stocks, and encourage many investors to hold Stocks for the medium to long term. There is an anticipated movement to expand the investor base.
Kaiomu --- fell back, announced the extension of the contract period for the basic contract of commissioned research Trade with Chugai Pharmaceutical.
The price fell. After the close of trade on the 18th, it was announced that the contract period of the basic agreement for commissioned research with Chugai Pharmaceutical was extended, but the unfavorable market conditions led to a prevailing selling pressure. The company signed a memorandum of changes to the basic agreement for commissioned research with Chugai Pharmaceutical, further extending the contract period specified in the original contract dated June 30, 2011 (previous extension disclosed on October 18, 2021, until December 31, 2024).
Chiome Bioscience Extends Master Services Agreement With Chugai Pharmaceutical
No Data